Treatment of Central Fever
Central (neurogenic) fever should be promptly treated with controlled normothermia targeting 36.0-37.5°C using automated feedback-controlled temperature management devices, as antipyretics alone have limited efficacy in this condition. 1
Primary Treatment Approach
The most recent high-quality guidelines from ESICM/NACCS (2024) establish that neurogenic fever (core temperature >37.5°C) driven by neurological dysregulation must be treated immediately with controlled normothermia regardless of intracranial pressure level 1. This represents a critical shift from traditional fever management, as central fever precipitates secondary brain injury and worsens outcomes 1.
Temperature Management Strategy
- Target range: 36.0-37.5°C using automated feedback-controlled devices 1
- Temperature variability limits: ≤±0.5°C per hour and ≤1°C per 24-hour period 1
- Duration: Continue as long as the brain remains at risk of secondary injury 1
The guidelines explicitly note that antipyretics (acetaminophen/NSAIDs) have limited efficacy in controlling central fever and minimizing temperature variability in severe brain injury 1. This is a crucial clinical pitfall—relying solely on pharmacologic antipyretics will fail in neurogenic fever.
Monitoring Requirements
Use central temperature monitoring methods when accurate measurements are critical 2:
- Pulmonary artery catheter thermistors
- Bladder catheters
- Esophageal balloon thermistors
- If unavailable: oral or rectal temperatures (avoid axillary, tympanic, temporal artery methods)
Pharmacologic Adjuncts
While automated cooling is primary, some pharmacologic options exist:
Beta-Blockers (Propranolol)
Research evidence supports propranolol 20-30 mg every 6 hours for central fever associated with autonomic dysregulation (tachycardia, hypertension, sweating, posturing) 3, 4. Temperature reduction of ≥1.5°C typically occurs within 48 hours 4. This addresses the underlying autonomic dysfunction rather than just temperature.
NSAIDs (Limited Role)
One case report describes continuous low-dose IV diclofenac (75 mg in 50 mL saline infusion) after initial bolus for stroke-related central fever 5. However, this represents low-quality evidence and should not replace automated temperature control.
Critical Diagnostic Consideration
You must exclude infectious causes before diagnosing central fever 1, 6. The 2023 SCCM/IDSA guidelines recommend against routine antipyretic use in critically ill patients with fever 2, but this applies to general ICU fever—not confirmed central fever where temperature control is mandatory.
Key differentiating features of central fever 7:
- Earlier onset (median day 2 vs day 6 for infectious fever)
- Hypothalamic/midbrain lesion involvement (particularly left-sided)
- Absence of elevated inflammatory markers (CRP, procalcitonin, leukocytosis)
- Negative infectious workup
Clinical Algorithm
- Detect fever (core temp >37.5°C) in neurologically injured patient
- Initiate infectious workup per SCCM/IDSA guidelines 2
- Simultaneously begin automated temperature control targeting 36.0-37.5°C 1
- If autonomic dysregulation present: Add propranolol 3, 4
- Continue temperature control throughout acute phase when secondary brain injury risk persists 1
Important Caveats
- Do not wait for infectious workup completion to initiate temperature control—hyperthermia causes harm regardless of etiology 1
- Non-automated cooling methods (ice packs, fans) provide poor control and should only supplement automated devices during induction 1
- The harmful effects of fever on brain metabolism, ICP, and tissue oxygenation occur whether fever is infectious or neurogenic 1
- Some controlled pyrexia may be tolerated in the subacute phase after acute injury risk has passed 1